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Abstract 
The marine environment remains a rich source for the discovery and development of novel 
bioactive compounds. The present paper describes the design, synthesis and biological 
evaluation of a library of small molecule heterocyclic mimetics of the marine 2,5-
diketopiperazine barettin which is a powerful natural antioxidant. By mainly focusing on the 
influence from the brominated indole and heterocyclic core of barettin, a library of 19 
compounds was prepared. The compounds comprised a heterocyclic core, either a 2,5 
diketopiperazine, an imidazolidinedione or a thioxothiazolidinone, which were mainly 
monosubstituted with ranging bulky substituents. The prepared compounds were screened for 
activity in a cellular lipid peroxidation assay using HepG2 cells. Several of the synthetic 
compounds showed antioxidant properties superior to the positive control barettin. Two of the 
prepared compounds displayed inhibitory activity similar to commercial antioxidants with 
significant inhibition at low µg/mL concentrations. The toxicity of the compounds was also 
investigated against MRC-5 lung fibroblasts and none of the included compounds displayed 
any toxicity at 50 µg/mL. 
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Introduction 
The 2,5-diketopiperazine (DKP) motif is found in numerous bioactive natural products, 
terrestrial and marine alike and represent the smallest cyclic peptide. The bioactivity of 
natural DKPs and their synthetic mimics differs vastly and was recently extensively reviewed 
by Borthwick[1]. A highly relevant example from a drug discovery perspective is the 2,5-
DKP phenylahistin initially isolated from Aspergillus ustus NSC-F038 by Fukumoto and co-
workers[2]. Phenylahistin exhibits strong cell cycle inhibitory properties and it was modified 
synthetically to yield the improved analog plinabulin which has been investigated in a range 
of clinical studies against several types of tumors[3-7]. Plinabulin and analogs thereof are 
potent microtubuli depolymerisation agents with low nanomolar inhibitory concentrations[4]. 
A related and also particularly interesting 2,5-DKP is barettin which was originally isolated 
from the marine boreal deep-water sponge Geodia barretti[8]. Barettin (cyclo-Arg-(6-Br)- 
dehydro-Trp) has been ascribed numerous bioactivities of which its ability to prevent 








In addition, barettin was recently shown by Lind and co-workers to display potent antioxidant 
and anti-inflammatory effects and it was suggested that the compound may have an 
  
atheroprotective effect[11]. Only barettin and a debrominated analog were studied in the 
paper by Lind et.al. which limited the insights into the structure activity relationship of the 
structural contributions to activity.  
 
Antioxidants can prevent the damage induced by oxidative stress and free radicals and several 
diseases such as cardiovascular disease, diabetes, cancer and inflammation have been 
associated with oxidative damage[12-13]. Several studies have reported seemingly beneficial 
effects with regards to the prevention or delayed progression of these diseases by antioxidants 
but this has rarely been supported by larger scale clinical studies[14-15]. While observations 
from clinical trials into the actual effects of antioxidants remain inconsistent, several 
observational epidemiologic studies still imply that antioxidants can lower the prevalence of 
certain diseases where oxidative damage is involved[16-17]. 
 
Based on the potent antioxidant activity of barettin we decided to investigate this natural 
scaffold further with simplified synthetic compounds in analogy to our ongoing work on 
transferring natural pharmacophores onto DKP scaffolds[18]. The initial focus was on the 
influence of the heterocyclic core of barettin and also the role of the brominated indole 
substituent. In Nature Trp is often found in DKPs and several hundred 2,5-DKPs natural 
product have been reported in the literature[1].  For this purpose, a library of 19 analogs of 
ranging structural complexity was designed and the compounds were evaluated as inhibitors 
of the cellular lipid peroxidation in HepG2 cells. In addition, the potential cytotoxic effect of 
the prepared compounds was further investigated using MRC-5 cells. 
 
Results and discussion 
Compound design and synthesis 
During the course of the present study, 19 heterocyclic compounds were designed and 
synthesised. Their preparation (yields reported solely for novel compounds) and biological 
evaluation is presented in the following sections. While barettin represents a natural 
promising antioxidant lead it still remains a complicated compound to produce synthetically 
in significant amounts. Relying on the isolation of natural products from natural sources is 
rarely a viable option for extensive studies and the synthesis of barettin was reported by 
Johnson et al. in 2004[19]. However, despite recent synthetic improvements such as those 
recently reported by Kelley et al.[20] who employed iterative aldol condensations to 
  
effectively generate monoalkylidene diketopiperazines, the enantioselective synthesis of 
barettin remains a low yielding synthesis. From a rational drug design perspective a removal 
of the chiral component of barettin would simplify the preparation significantly. This strategy 
was also successfully employed during the transformation of phenylahistin into plinabulin[1]. 
As a removal of the charged guanidine of barettin may also increase potential passive uptake 
properties[21] it was decided to focus on compounds without a charged chiral component 
with the main focus on the nature of the brominated indole substituent. To further probe the 
structure activity relationship of the prepared compounds, both imidazolidinedione and 
thioxothiazolidinone cores where also investigated in addition to the original 2,5-DKP 
scaffold. 
 
Compound 1 was synthesised as described in the literature[22]. Compounds 4 and 7 were 
prepared from the reaction between the Boc-protected aldehyde 2 or 6 and the 1,4-
diacetylpiperazine-2,5-dione 3[23]. Deprotection was carried out using hydrazine hydrate to 











Scheme 1. Structure of compound 1. Preparation of compound 5 and 8. Reagents and conditions: (a) t-BuOK in 
THF, t-BuOH, NMP, RT, 24 h (4: 76 %, 7: 50 %); (b) hydrazine hydrate, RT, 24 h (5: 73 %, 8: 67 %). 
 
By changing the reaction conditions and also the number of equivalents of 2, it was possible 












Scheme 2. Preparation of compound 9. Reagents and conditions: (a) Cs2CO3, NMP, RT, 36 h; TFA, CH2Cl2, RT, 
2 h (63 %). 
 
In order to add additional hydrophobic bulk to the indole, compounds 5 and 8 were further 
functionalised using Suzuki coupling[26]. Compound 5 was reacted with phenylboronic acid, 
4-methoxyphenylboronic acid and 4-chlorophenylboronic acid to yield 10, 11 and 12 














Scheme 3. Preparation of compound 10, 11 and 12. Reagents and conditions: (a) PdCl2(PPh3)2, K2CO3, 
THF/H2O, 60 °C, 16 h (10: 79 %, 11: 72 %, 12: 44 %). 
 
In a similar fashion, 8 was reacted with the same set of boronic acids to afford compounds 13, 

















Scheme 4. Preparation of compound 13, 14 and 15. Reagents and conditions: (a) PdCl2(PPh3)2, K2CO3, 
THF/H2O, 60 °C, 48 h (13: 79 %, 14: 72 %, 15: 89 %). 
 
Structurally simpler analogs of the brominated indole of barettin were also included and 
prepared using 3 and a series of simple benzaldehydes. Compound 3 was reacted with the 
aldehydes 16, 17 and 18 to afford the mono-acetyl derivatives 19[27-28], 20 and 21 which 









Scheme 5. Preparation of compounds 19-21 and 22-24. Reagents and conditions: (a) NEt3, NMP, RT, 16 h (20: 
45 %, 21: 80 %); (b) hydrazine hydrate, RT, 2 h (23: 99 %, 24: 92 %). 
 
By reacting the bromoindole aldehydes 25 and 26 with hydantoin (27), the central core of the 
barettin was replaced with a 2,4-imidazolidinedione core, to yield the derivatives 28 and 29 in 
a single step condensation[30]. Indole hydantoin derivatives represent interesting compounds 
  
and they have recently been shown to be promising p53-MDM2 binding inhibitors with IC50 
values down to 33 nM reported[31]. Reaction of the same hydantoin 27 with the aldehyde 30 












Scheme 6. Preparation of compounds 28, 29 and 31. Reagents and conditions: (a) piperidine, reflux, 1 h (28: 18 
%, 29: 10 %, 31: 28 %). 
 
In addition, the thioxothiazolidinone derivatives 33 and 34 were prepared as described in the 
literature by condensation of the aldehydes 25 and 26 with rhodanine 32[32]. The 
thioxothiazolidinone core represents a versatile scaffold that can be reacted with both 
nucleophiles and electrophiles, that has been used to generate a range of different biologically 
active compounds[33-34]. Following the same procedure, the thioxothiazolidinone 35 was 













Scheme 7. Preparation of compound 33, 34 and 35. Reagents and conditions: (a) AcONa, ACOH, reflux, 2 h, 
(35: 47 %). 
The prepared compounds were generally prepared in acceptable yields (reported only for the 































Figure 1. Structures of the prepared compounds. 
Bioactivity testing 
Following synthesis and purification, the compounds were investigated as inhibitors in a 
cellular lipid peroxidation antioxidant assay employing HepG2 cells. In the CLPAA assay the 
lipid peroxidation is initiated by the addition of cumene hydroperoxide and the inhibition by 
the compounds can be evaluated using fluorescence after the addition of the reactive oxygen 
species marker C-11-BODIPY[36]. Initially the compounds were screened at a concentration 
of 50 µg/mL to assess their inhibitory potential. Compounds displaying sufficient inhibition 
(<50 % remaining activity) were considered as active and were included in a dose-response 
analysis to establish their EC50 values as summarised in Table 1 and Figure 2.  
 




Activity [50 µg/mL] 50 % inhibition [µg/mL]3 
2,5-Diketopiperazines     




5 320.15 1.450 a
2
  10 
8 320.15 1.450 na nt 
9 526.19 3.436 a  12 
10 317.35 2.307 a  25 
11 347.37 2.226 na nt 
12 351.79 3.010 a  5 
13 317.35 2.307 na nt 
14 347.37 2.227 na nt 
15 351.79 3.010 a  10 
22 202.21 0.429 na nt 
23 236.66 1.142 na nt 
24 281.11 1.292 a  >75 
Barettin 419.28 0.299 a  30 
Imidazolidinediones     
28 306.12 2.023 a  20 
29 306.12 2.023 a  >75 
31 277.28 2.166 a  2.5 
Thioxothiazolidinones     
33 339.23 2.823 na nt 
34 339.23 2.823 na nt 
35 310.39 2.966 na nt 
     
1
Calculated values using ChemBioDraw Ultra 
2















Figure 2. Left: Dose-response analysis of the antioxidant properties of selected compounds in the CLPAA assay; 
-Δ- compound 5, -□- compound 15 and -×- compound 29. Right: Dose-response analysis of the antioxidant 
properties of compound 31 at a lower concentration range. 
 
The potential toxicity on human lung fibroblasts (MRC-5 cells) was also evaluated using a 
commonly employed MTT-assay. Barettin has previously been reported to display no 
reduction in viability at concentrations up to 100 µg/mL, (maximum concentration 
investigated) against both HepG2 and MRC-5 cells. The prepared compounds were thus 
investigated for toxic activity against MRC-5 cells in an analogous fashion, initially at a 
concentration of 50 µg/mL. At 50 µg/mL, none of the compounds induced a decrease in 
MRC-5 viability (data not shown) and subsequently none of the compounds were evaluated in 
further dose-response studies. 
 
Structure-activity-relationship 
The recent study on barettin and its debromo analog debromobarettin revealed a CLPAA 
inhibition of 50 % at 30 µg/mL (relative to the positive control cumene hydroperoxide)[11]. 
Debromobarettin was inactive as inhibitor implying that the influence of the halogen 
substituent is of major importance for the inhibitory ability of the disubstituted 2,5-DKP 
scaffold. Removal of the bromine has also been observed to negatively affect the antifouling 
properties of barettin derivatives[37]. The two compounds were also compared to the 
commercially employed synthetic antioxidant butylated hydroxytoluene (BHT) which was 
significantly more potent with a 75 % reduction of oxidation at a concentration of 10 µg/mL[11]. 
 
The current library includes significantly simplified and rational structures inspired by the 
structure of the naturally occurring barettin. The prepared compounds are achiral and none of the 
  
compounds bear the cationic arm of barettin. Instead focus lies on hydrophobic substituents, 
halogenation and alternative heterocyclic cores. 
 
As shown in table 1, 10 out of the 20 analysed compounds (including barettin) displayed 
inhibition of cumene hydroperoxide induced lipid peroxidation. It is interesting to see that 
several of these simplified compounds are active despite the absence of the chiral cationic 
side chain found in natural barettin. Dose response analysis revealed that several of the 
compounds (compounds 5, 9, 10, 12, 15, 28 and 31) displayed improved antioxidative 
activities in comparison to those of barettin. The most potent inhibitors were compounds 12 
and 31 which displayed low EC50 values of 5 and 2.5 µg/mL respectively. Both of those 
compounds also revealed a 75 % inhibition at 10 µg/mL, which is similar to that of the 
commercial antioxidant BHT indicating a particularly strong antioxidant activity[11]. These 
two compounds are also superior in inhibition to the positive antioxidant control luteolin 
which was included at 50 µg/mL (Table S1 in Supporting information) in the CLPAA assay. 
 
All compounds in the prepared library are noncharged, small, with theoretical ClogP values 
ranging from 0.419 to 3.436. Compound 9 substituted with two 6-bromoindoles stands out as 
both the largest and most hydrophobic compound in the library. Compound 9 is indeed an 
active inhibitor but several of the other compounds display similar activities while being both 
smaller and more hydrophilic so there appears to be no clear-cut link between size and 
polarity and activity.  
 
As three different heterocyclic cores have been used to generate the libraries it is also relevant 
to consider the SAR from this perspective. Active compounds 5, 9, 10, 12, 15 and 24 are all 
2,5-DKPs. Upon dose-response analysis of compound 24 an EC50-value >75 µg/mL was 
obtained suggesting that this compound is not very active. The remaining five active 2,5-
DKPs display EC50 values between 5 and 25 µg/mL. Of the smaller compounds 1, 5, 8, 22, 23 
and 24 only compound 5 displays a pronounced activity with 10 µg/mL EC50-values. 
Compound 5 is brominated in the 6-position whereas inactive compound 8 is brominated in 
the 7-position. In barettin, the 6-position is brominated and the clear difference between 5 and 
8 implies that this is a beneficial position for activity. In analogy to 8, and also previous 
studies on debromobarettin, the non brominated analog 1 is also inactive[11,37]. Compounds 
22, 23, 24 were designed with smaller substituted phenyls instead of indoles and none of them 
  
are regarded as active. The larger compounds (10-15) prepared from 5 and 8 by additional 
Suzuki couplings contained several active compounds. Both compounds 10 and 12 were 
active with a pronounced activity seen for the para-chlorinated analog 12 (EC50 = 5 µg/mL). 
Compounds 13-15, substituted in the indole 7-position from 8 are less active than their indole 
6-analogs. Para-chlorinated compound 15 still remains highly active (EC50 = 10 µg/mL) but 
inferior to its indole 6-analog (12). Three brominated boronic acids (2-, 3- and 4-
bromophenylboronic acid) were initially evaluated in the Suzuki couplings with an aim to 
generate brominated analogs. However due to multiple side-reactions and polymerisations, 
the strategy was abandoned in favor of the chlorinated alternatives (12 and 15). To conclude 
the 2,5-DKP library, it appears that halogenated compounds are more active. With regards to 
substitution patterns it also appears that the 6-position on the indole is beneficial as actives 5, 
9, 10 and 12 all share this substitution pattern while the chlorinated 15 represents the only 
active 2,5-DKP substituted in the 7-position. It also evident that the larger compounds are 
more active than the smaller ones in this library. 
 
Moving over to hydantoin derivatives 28, 29 and 31, all displaying an imidazolidinedione 
moiety, these derivatives all displayed antioxidant activity in the initial screen at 50 µg/mL. 
This illustrates that this scaffold is also suited for the generation of effective inhibitors. Both 
the 2,5-DKP and the imidazolidinedione scaffold display a comparable ability to engage in 
potential hydrogen bonding interactions and they appear equally suited for the generation of 
this type of compounds.  For compound 29, the activity initially observed in the screen was 
determined to be somewhat lower in the dose-response analysis in a similar fashion as for 24 
with an EC50-value >75 µg/mL. Worth noting is that compound 24 also is substituted in the 7-
position on the indole which is in agreement with the lower activity seen for the DKP library 
discussed in the previous section. The 6-indole analog 28 was an active inhibitor (EC50 = 20 
µg/mL) which also correlates well with the SAR for the DKPs. Introduction of the bulky 
aldehyde 30 generated compound 31 which is not halogenated. Despite this, compound 31 
represent the most active of all the prepared compounds with a low EC50 of 2.5 µg/mL. This is 
superior to compound 12 and suggest that these two compounds display antioxidant activity 
equal to BHT in this assay[11]. 
 
Compounds 33-35, represent thioxothiazolidinone derivatives of 28, 29 and 31, and were 
prepared from rhodanine. Interestingly none of these compounds were active in the initial 
  
screen which was unexpected given that all the imidazolidinedione derivatives were active in 
the initial screen and also generated the most active compound (31) in this study. This 
observation implies that the sulfur containing thioxothiazolidinone ring impairs the 





In the present study 19 synthetic heterocyclic antioxidants have been prepared and evaluated 
for their ability to inhibit cumene hydroperoxide induced lipid peroxidation. The library 
contains compounds inspired by the natural brominated marine antioxidant and antifoulant 
barettin all of which are considerably simplified structurally. Several of the prepared 
compounds displayed potent inhibitory activities superior to barettin with two compounds 
exhibiting inhibitory properties comparable to commercially employed antioxidants. The high 
inhibitory potency observed for the most active compounds suggest that these compounds 
should be further studied and refined in the future. For the current library, the inhibitory 
activity is linked to the nature and position of the indole substituents. The imidazolidinedione 
scaffold compares well with natural 2,5-DKP scaffold while none of the compounds 
incorporating a thioxothiazolidinone ring were active. The study highlights how it is possible 






NMR spectra were acquired on a Varian 7000e 400 MHz spectrometer and HRMS was 
performed employing an LTQ Orbitrap XL Hybrid Fourier Transform mass spectrometer 
from Thermo Scientific. Reagents and solvents were obtained from commercial suppliers and 
used without further purification. Air-sensitive reactions were carried out under an argon 
atmosphere. Reaction were monitored by thin-layer chromatography which was carried out on 
aluminum-backed plates coated with silica gel and visualised under UV light at 254 nm and 







To a solution of 1,4-diacetylpiperazine-2,5-dione (1.4 g, 6.8 mmol, 2.0 eq.) and tert-butyl 6-
bromo-3-formyl-1H-indole-1-carboxylate (1.1 g, 3.4 mmol, 1.0 eq.) in a mixture of anhydrous 
tert-butanol (5 mL) and NMP (10 mL) was added at 0 °C a solution of potassium tert-
butoxide in THF (1M, 5.1 mL, 5.1 mmol, 1.5 eq.). The mixture was stirred at room 
temperature for 24 h and then, diluted with water. The resulting precipitate was filtered, 
washed with ethanol and diethyl ether to afford 4 as a pale yellow solid (1.2 g, 76 %). 
1
H 
NMR (DMSO-d6, 400 MHz):  (ppm): 2.51 (s, 3H), 4.38 (s, 2H), 7.09 (s, 1H), 7.50 (dd, J = 
8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 8.18 (s, 1H), 8.24 (d, 1H), 10.42 (s, 1H). 
13
C NMR 
(DMSO-d6, 100 MHz):  (ppm): 27.2, 28.0, 46.2, 85.7, 109.0, 113.1, 118.0, 118.2, 126.6, 





: m/z = 460.0503, found: 460.0513. 
 
(Z)-3-[(6-bromo-1H-indol-3-yl)methylene]piperazine-2,5-dione (5) 
To a solution of 4 (280 mg, 0.60 mmol, 1.0 eq.) in NMP (5 mL) was added hydrazine hydrate 
(294 µL, 6.0 mmol, 10.0 eq.). The mixture was stirred at room temperature for 24 h and then, 
diluted with water. The precipitate was filtered, washed with ethanol, acetone and MTBE to 
afford 5 as a pale yellow solid (140 mg, 73 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 
4.00 (s, 2H), 6.94 (s, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.60 (m, 1H), 7.61 (s, 1H), 7.94 (s, 1H), 
8.94 (s, 1H), 9.54 (s, 1H), 11.74 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 44.9, 
106.7, 108.1, 114.3, 114.6, 120.0, 122.6, 123.3, 126.0, 127.1, 136.5, 160.5, 164.5. FTMS (-








To a solution of 1,4-diacetylpiperazine-2,5-dione (2.5 g, 12.6 mmol, 1.5 eq.) and tert-butyl 7-
bromo-3-formyl-1H-indole-1-carboxylate (2.7 g, 8.3 mmol, 1.0 eq.) in a mixture of anhydrous 
tert-butanol (20 mL) and NMP (20 mL) was added at 0 °C a solution of potassium tert-
butoxide in THF (1M, 13 mL, 13.0 mmol, 1.6 eq.). The mixture was stirred at room 
temperature for 24 h and then, diluted with water. The resulting cloudy mixture was extracted 
  
with acetone and ethyl acetate, and then, washed with a saturated ammonium chloride 
solution. The organic layer was dried over Na2SO4, filtered through a silica gel pad and 
evaporated under reduced pressure to afford, after trituration with MTBE, 7 (1.9 g, 50 %) as a 
pale yellow solid. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 1.65 (s, 9H), 2.52 (s, 3H), 4.39 
(s, 2H), 7.08 (s, 1H), 7.27 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 7.6 Hz, 
1H), 8.15 (s, 1H), 10.42 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 26.8, 27.4, 45.8, 
85.5, 107.3, 108.7, 112.3, 118.8, 124.9, 127.2, 129.9, 130.2, 132.7, 148.0, 161.3, 164.2, 171.9. 




: m/z = 460.0514, found: 460.0523. 
  
(Z)-3-[(7-bromo-1H-indol-3-yl)methylene]piperazine-2,5-dione (8) 
To a solution of 7 (900 mg, 2.0 mmol, 1.0 eq.) in NMP (4 mL) was added hydrazine hydrate 
(0.76 mL, 15.6 mmol, 8.0 eq.). The mixture was stirred at room temperature for 24 h and then, 
diluted with water. The precipitate was filtered, washed with ethanol and MTBE to afford 8 as 
a yellow solid (140 mg, 67 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 4.00 (s, 2H), 6.94 
(s, 1H), 7.05 (m, 1H), 7.39 (d, J = 6.4 Hz, 1H), 7.66 (d, J = 6.4 Hz, 1H), 7.96 (s, 1H), 8.16 (s, 
1H), 9.67 (s, 1H), 11.82 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 44.8, 104.5, 





: m/z = 317.9884, found: 317.9887. 
 
(3Z,6Z)-3,6-bis[(6-bromo-1H-indol-3-yl)methylene]piperazine-2,5-dione (9) 
To a solution of 1,4-diacetylpiperazine-2,5-dione (0.24 g, 1.2 mmol, 1.0 eq.) and tert-butyl 6-
bromo-3-formyl-1H-indole-1-carboxylate (1.0 g, 3.1 mmol, 2.6 eq.) in NMP (6 mL) was 
added cesium carbonate (1.3 g, 3.6 mmol, 3.0 eq.). The mixture was stirred at room 
temperature for 36 h and then, diluted with water. The precipitate that formed was filtered, 
taken up in acetone and the volatiles were removed under reduced pressure. The residue was 
taken up in dichloromethane (10 mL) and TFA (6 mL), and the resulting solution was stirred 
at room temperature for 2 h. The mixture was quenched with water, basified with NaOH 1M 
and extracted with ethyl acetate and Et2O. The organic layer was filtered and the precipitate 
washed with MTBE to afford 9 as a dark yellow solid (400 mg, 63 %). 
1
H NMR (DMSO-d6, 
400 MHz):  (ppm): 7.03 (s, 2H), 7.25 (dd, J = 8.5 Hz, J = 1.5 Hz 2H), 7.63 (d, J = 1.5 hz, 
2H), 7.66 (d,  J = 8.5 Hz, 2H), 8.12 (s, 2H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 107.0, 









To a mixture of 5 (50 mg, 0.16 mmol, 1.0 eq.) in a mixture of degassed THF (4 mL) and 
water (2 mL) were added, under an argon atmosphere, phenylboronic acid (29 mg, 0.24 
mmol, 1.5 eq.), K2CO3 (65 mg, 0.48 mmol, 3.0 eq.) and PdCl2(PPh3)2 (11 mg, 0.016 mmol, 
0.1 eq.). The reaction was stirred at 60 °C for 16 h and then, diluted with water after cooling 
to room temperature. The mixture was extracted with ethyl acetate, filtered and the precipitate 
was washed with ethanol, dichloromethane and MTBE to afford 10 (40 mg, 79 %) as a dark 
yellow solid. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 4.01 (s, 2H), 7.02 (s, 1H), 7.34 (t, J = 
7.0 Hz, 1H), 7.45 (m, 3H), 7.70 (m, 4H), 7.98 (s, 1H), 8.12 (s, 1H). 
13
C NMR (DMSO-d6, 100 
MHz):  (ppm): 44.9, 107.4, 107.9, 109.7, 118.6, 119.2, 122.8, 126.7, 127.0, 128.9, 134.5, 
136.3, 141.2, 160.6, 164.4. FTMS (-ESI): calcd for C19H14O2N3
-




To a mixture of 5 (50 mg, 0.16 mmol, 1.0 eq.) in a mixture of degassed THF (4 mL) and 
water (2 mL) were added, under an argon atmosphere, 4-methoxyphenylboronic acid (36 mg, 
0.23 mmol, 1.5 eq.), K2CO3 (65 mg, 0.47 mmol, 3.0 eq.) and PdCl2(PPh3)2 (11 mg, 0.016 
mmol, 0.1 eq.). The reaction was stirred at 60 °C for 16 h and then, diluted with water after 
cooling to room temperature. The mixture was extracted with ethyl acetate, filtered and the 
precipitate was washed with ethanol, dichloromethane and MTBE to afford 11 (40 mg, 72 %) 
as a grey solid. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 3.80 (s, 3H), 4.01 (s, 2H), 7.02 (m, 
3H), 7.38 (d, J = 8.0 Hz, 1H), 7.61 (m, 3H), 7.68 (d, J = 8.0 Hz, 1H), 7.95 (s, 1H), 8.12 (s, 
1H), 9.49 (s, 1H), 11.67 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 44.9, 55.2, 107.5, 
107.8, 109.1, 114.3, 118.5, 119.0, 122.7, 125.9, 126.8, 127.8, 133.6, 134.3, 136.4, 158.4, 
160.7, 164.5. FTMS (-ESI): calcd for C20H16O3N3
-
: m/z = 346.1197, found: 346.1194. 
 
(Z)-3-{[6-(4-chlorophenyl)-1H-indol-3-yl]methylene}piperazine-2,5-dione (12) 
To a mixture of 5 (50 mg, 0.16 mmol, 1.0 eq.) in a mixture of degassed THF (4 mL) and 
water (2 mL) were added, under an argon atmosphere, 4-chlorophenylboronic acid (38 mg, 
0.23 mmol, 1.5 eq.), K2CO3 (65 mg, 0.47 mmol, 3.0 eq.) and PdCl2(PPh3)2 (11 mg, 0.016 
mmol, 0.1 eq.). The reaction was stirred at 60 °C for 16 h and then, diluted with water after 
cooling to room temperature. The mixture was extracted with ethyl acetate, filtered and the 
  
precipitate was washed with ethanol, dichloromethane and MTBE to afford 12 (25 mg, 44 %) 
as a grey solid. 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 4.02 (s, 2H), 7.02 (s, 1H), 7.42 (d, J 
= 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.68 (s, 1H), 7.73 (d, J = 8.0 Hz, 3H), 8.00 (s, 1H), 
9.54 (s, 1H), 11.76 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 44.9, 107.3, 107.9, 
109.8, 118.7, 119.1, 122.9, 126.7, 127.3, 128.5, 128.8, 131.5, 133.1, 136.3, 140.0, 160.7, 




: m/z = 350.0702, found: 350.0699. 
 
(Z)-3-[(7-phenyl-1H-indol-3-yl)methylene]piperazine-2,5-dione (13) 
To a mixture of 8 (100 mg, 0.32 mmol, 1.0 eq.) in a mixture of degassed THF (8 mL) and 
water (4 mL) were added, under an argon atmosphere, phenylboronic acid (78 mg, 0.64 
mmol, 2.0 eq.), K2CO3 (130 mg, 0.47 mmol, 3.0 eq.) and PdCl2(PPh3)2 (22 mg, 0.031 mmol, 
0.1 eq.). The reaction was stirred at 60 °C for 48 h and then, diluted with water after cooling 
to room temperature. The precipitate was filtered and the residue was washed with ethanol, 
dichloromethane and MTBE to afford 13 (80 mg, 79 %) as a grey solid. 
1
H NMR (DMSO-d6, 
400 MHz):  (ppm): 4.00 (s, 2H), 7.02 (s, 1H), 7.21 (m, 2H), 7.44 (m, 1H), 7.55 (d, J = 7.4 
Hz, 2H), 7.63 (m, 3H), 7.90 (s, 1H), 8.12 (s, 1H), 9.64 (s, 1H), 11.49 (s, 1H). 
13
C NMR 
(DMSO-d6, 100 MHz):  (ppm): 44.9, 107.3, 108.2, 117.3, 120.5, 122.3, 122.9, 125.7, 127.0, 
127.4, 128.0, 128.3, 129.0, 132.8, 138.3, 160.8, 164.6. FTMS (-ESI): calcd for C19H14O2N3
-
: 
m/z = 316.1092, found: 316.1085. 
 
(Z)-3-{[7-(4-methoxyphenyl)-1H-indol-3-yl]methylene}piperazine-2,5-dione (14) 
To a mixture of 8 (100 mg, 0.32 mmol, 1.0 eq.) in a mixture of degassed THF (8 mL) and 
water (4 mL) were added, under an argon atmosphere, 4-methoxyphenylboronic acid (97 mg, 
0.64 mmol, 2.0 eq.), K2CO3 (130 mg, 0.47 mmol, 3.0 eq.) and PdCl2(PPh3)2 (22 mg, 0.031 
mmol, 0.1 eq.). The reaction was stirred at 60 °C for 48 h and then, diluted with water after 
cooling to room temperature. The precipitate was filtered and the residue was washed with 
ethanol, dichloromethane and MTBE to afford 14 (80 mg, 72 %) as a dark yellow solid. 
1
H 
NMR (DMSO-d6, 400 MHz):  (ppm): 3.85 (s, 3H), 4.00 (s, 2H), 7.03 (s, 1H), 7.12 (d, J = 8.6 
Hz, 2H), 7.15 (m, 1H), 7.20 (t, J = 7.4 Hz, 1H), 7.57 (d, J = 8.6 Hz, 2H), 7.61 (d, J = 7.4 Hz, 
1H), 7.90 (s, 1H), 8.12 (s, 1H), 9.63 (s, 1H), 11.44 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz): 
 (ppm): 44.9, 55.3, 107.5, 108.2, 114.4, 116.9, 120.5, 122.0, 122.8, 125.6, 127.0, 127.9, 
129.5, 132.9, 158.7, 160.9, 164.6. FTMS (-ESI): calcd for C20H16O3N3
-





To a mixture of 8 (100 mg, 0.32 mmol, 1.0 eq.) in a mixture of degassed THF (8 mL) and 
water (4 mL) were added, under an argon atmosphere, 4-chlorophenylboronic acid (100 mg, 
0.64 mmol, 2.0 eq.), K2CO3 (130 mg, 0.47 mmol, 3.0 eq.) and PdCl2(PPh3)2 (22 mg, 0.031 
mmol, 0.1 eq.). The reaction was stirred at 60 °C for 48 h and then, diluted with water after 
cooling to room temperature. The precipitate was filtered and the residue was washed with 
ethanol, dichloromethane and MTBE to afford 15 (100 mg, 89 %) as a grey solid. 
1
H 
NMR (DMSO-d6, 400 MHz):  (ppm): 4.00 (s, 2H), 7.02 (s, 1H), 7.23 (m, 2H), 7.60 (d, J = 
8.2 Hz, 2H), 7.66 (m, 3H), 7.93 (s, 1H), 8.13 (s, 1H), 9.64 (s, 1H), 11.53 (s, 1H). 
13
C NMR 
(DMSO-d6, 100 MHz):  (ppm): 44.9, 107.2, 108.4, 117.9, 120.5, 122.3, 123.0, 124.5, 127.1, 





: m/z = 350.0702, found: 350.0697. 
 
(Z)-1-acetyl-3-(4-chlorobenzylidene)piperazine-2,5-dione (20) 
To a solution of 1,4-diacetylpiperazine-2,5-dione (1.0 g, 5.0 mmol, 1.0 eq.) and 4-
chlorobenzaldehyde (703 mg, 5 mmol, 1.0 eq.) in NMP (3 mL) was added triethylamine (0.7 
mL, 5.0 mmol, 1.0 eq.). The mixture was stirred at room temperature for 16 h and then, 
diluted with water. The resulting precipitate was filtered, washed with acetone and MTBE to 
afford 20 as a beige solid (800 mg, 45 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 4.36 (s, 
2H), 6.93 (s, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 10.43 (s, 1H). 
13
C NMR 
(DMSO-d6, 100 MHz):  (ppm): 26.7, 45.6, 117.4, 127.5, 128.6, 131.3, 132.0, 133.0, 161.5, 




: m/z = 277.0385, found: 277.0387. 
 
(Z)-1-acetyl-3-(4-bromobenzylidene)piperazine-2,5-dione (21) 
To a solution of 1,4-diacetylpiperazine-2,5-dione (1.0 g, 5.0 mmol, 1.0 eq.) and 4-
bromobenzaldehyde (925 mg, 5 mmol, 1.0 eq.) in NMP (3 mL) was added triethylamine (0.7 
mL, 5.0 mmol, 1.0 eq.). The mixture was stirred at room temperature for 16 h and then, 
diluted with water. The resulting precipitate was filtered, washed with acetone and MTBE to 
afford 21 as a yellow solid (1.3 g, 80 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 4.36 (s, 
2H), 6.93 (s, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 10.28 (s, 1H). 
13
C NMR 
(DMSO-d6, 100 MHz):  (ppm): 26.7, 45.6, 117.4, 127.5, 128.6, 131.3, 132.0, 133.0, 161.5, 








To a mixture of 20 (200 mg, 0.72 mmol, 1.0 eq.) in NMP (2 mL) was added hydrazine 
hydrate (52 µL, 1.08 mmol, 1.5 eq.). The reaction was stirred at room temperature for 2 h. 
Water was added and the insoluble was filtered, washed with water and triturated with 
acetone and MTBE to afford 23 as a pale yellow solid (170 mg, 99 %). 
1
H NMR (DMSO-d6, 
400 MHz):  (ppm): 4.00 (s, 2H), 6.65 (s, 1H), 7.44 (m, 2H), 7.50 (m, 2H), 8.32 (s, 1H), 10.04 
(s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 44.8, 112.6, 127.6, 128.6, 131.0, 132.2, 








To a mixture of 21 (200 mg, 0.62 mmol, 1.0 eq.) in NMP (2 mL) was added hydrazine 
hydrate (45 µL, 0.93 mmol, 1.5 eq.). The reaction was stirred at room temperature for 2 h. 
Water was added and the insoluble was filtered, washed with water and triturated with 
acetone and MTBE to afford 24 as pale yellow solid (160 mg, 92 %). 
1
H NMR (DMSO-d6, 
400 MHz):  (ppm): 4.00 (s, 2H), 6.63 (s, 1H), 7.43 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 
2H), 8.32 (s, 1H), 10.05 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 45.2, 113.1, 





= 278.9775, found: 278.9774. 
 
(E)-5-[(6-bromo-1H-indol-3-yl)methylene]imidazolidine-2,4-dione (28) 
A mixture of hydantoin (446 mg, 4.46 mmol, 2.5 eq.) and 6-bromoindole-3-carboxaldehyde 
(400 mg, 1.78 mmol, 1.0 eq.) in piperidine (2 mL) was refluxed during 1 h. The mixture was 
cooled to room temperature, then diluted with acetone and ethyl acetate. The organic layer 
was washed with a 1 M HCl, dried over Na2SO4 and then evaporated under reduced pressure. 
The residue was triturated with ethyl acetate, ethanol and MTBE to afford 28 as an orange 
solid (250 mg, 18 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 6.70 (s, 1H), 7.22 (dd, J = 
8.4 Hz, J = 1.6 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 10.14 
(bs, 1H), 11.01 (bs, 1H), 11.92 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 100.9, 
108.6, 114.4, 115.0, 120.1, 122.9, 124.3, 125.9, 127.5, 136.6, 155.2, 165.3. MS: FTMS (-









A mixture of hydantoin (223 mg, 2.23 mmol, 2.5 eq.) and 7-bromoindole-3-carboxaldehyde 
(200 mg, 0.89 mmol, 1.0 eq.) in piperidine (1 mL) was refluxed during 1 h. The mixture was 
cooled to room temperature, then diluted with acetone and ethyl acetate. The organic layer 
was washed with a 1 M HCl, dried over Na2SO4 and then evaporated under reduced pressure. 
The residue was triturated with ethanol, dichloromethane, heptane and acetone to afford 29 as 
a dark yellow solid (70 mg, 10 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 6.70 (s, 1H), 
7.07 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 8.21 (s, 1H), 10.25 
(s, 1H), 11.08 (s, 1H), 11.99 (s, 1H). 
13
C NMR (DMSO-d6, 100 MHz):  (ppm): 100.8, 104.5, 





: m/z = 303.9727, found: 303.9727. 
 
(E)-5-[(1H-benzo[g]indol-3-yl)methylene]imidazolidine-2,4-dione (31) 
A mixture of hydantoin (256 mg, 2.56 mmol, 2.5 eq.) and 1H-benzo[g]indole-3-carbaldehyde 
(200 mg, 1.02 mmol, 1.0 eq.) in piperidine (1 mL) was refluxed during 2 h. The mixture was 
cooled to room temperature, then diluted with acetone and ethyl acetate. The organic layer 
was washed with water, dried over Na2SO4 and then evaporated under reduced pressure. The 
residue was triturated with ethanol and MTBE to afford 31 as a dark red solid (80 mg, 28 
%).
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 6.84 (s, 1H), 7.45 (t, J = 7.8 Hz, 1H), 7.57 (m, 
1H), 7.59 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 8.20 (m, 1H), 
8.38 (d, J = 7.8 Hz, 1H), 10.18 (s, 1H), 11.07 (s, 1H), 12.66 (s, 1H). 
13
C NMR (DMSO-d6, 
100 MHz):  (ppm): 101.7, 110.2, 118.1, 120.6, 120.9, 121.8, 122.8, 124.1, 124.2, 124.5, 
127.8, 128.4, 130.1, 130.5, 155.3, 165.4. FTMS (-ESI): calcd for C16H10N3O2
-
: m/z = 
276.0778, found: 276.0778. 
 
(Z)-5-[(1H-benzo[g]indol-3-yl)methylene]-2-thioxothiazolidin-4-one (35) 
A mixture of rhodanine (136 mg, 1.02 mmol, 1.0 eq.), sodium acetate (251 mg, 3.06 mmol, 
3.0 eq.) and 1H-benzo[g]indole-3-carbaldehyde (200 mg, 1.02 mmol, 1.0 eq.) in acetic acid (2 
mL) was refluxed during 2 h. The mixture was cooled to room temperature, then diluted with 
water and the precipitate was filtered to afford, after trituration with ethanol and MTBE, 35 as 
a red solid (150 mg, 47 %). 
1
H NMR (DMSO-d6, 400 MHz):  (ppm): 7.50 (t, J = 7.4 Hz, 
1H), 7.62 (t, J = 7.4 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 8.01 (d, J = 8.2 Hz, 1H), 
  
8.04 (m,  2H), 8.47 (d, J = 7.4 Hz, 1H), 13.15 (s, 1H), 13.61 (s, 1H). 
13
C NMR (DMSO-d6, 
100 MHz):  (ppm): 112.5, 118.1, 119.0, 120.8, 121.8, 122.1, 123.1, 124.7, 126.1, 127.2, 
128.5, 130.5, 131.3, 169.1, 194.8. FTMS (-ESI): calcd for C16H9N2OS2
-
: m/z = 309.0162, 
found: 309.0159. 
 
Cellular lipid peroxidation method 
HepG2 cells were cultured and assayed in MEM supplemented with Earle’s salt (E-MEM, 
Biochrom) further supplied with fetal bovine serum (10 % FBS, Merck), L-alanyl-L-glutamine 
(2 mM, Merck) and gentamycin (10 µg/mL Biochrom, A2712). The cells were seeded in 
black 96-well microtiter plates with clear bottom (Corning, 3603) at approximately 90000 
cells/well and incubated overnight in 5 % CO2 at 37 °C. The cell media was replaced and cells 
were washed with PBS. Total reaction volume was 100 μL. The cells were subsequently 
labelled with C11-BODIPY (Invitrogen, Eugene, OR, USA) for 30 min and incubated with 
ranging concentrations of the test compounds for 1 h. The compounds were prepared from a 
DMSO stock by addition of MQ-water, from which 20 µL were added to 80 µL of MEM to 
reach the desired final concentration (maximum final DMSO concentration was 0.5 %) in the 
wells. Cumene hydroperoxide (50 µM CumOOH final concentration, Sigma-Aldrich) was 
added to initiate lipid peroxidation and the plate was immediately installed in a Victor3 Plate 
Reader. Both red (590/7 nm (excitation), 632/45 nm (emission)) and green (485/14 nm, 
520/10 nm) fluorescence were recorded to follow the lipid peroxidation. Percent inhibition 
was calculated relative to the positive control (50 µM CumOOH without test compound). The 
antioxidant effect of known antioxidant luteolin at 50 µg/mL was used as positive antioxidant 
control and Hank’s saline solution without CumOOH was used as negative control to ensure 




The potential cytotoxic activity of the compounds was investigated at a concentration of 50 
µg/mL against human normal lung fibroblasts (MRC5). MRC5 cells were cultured and 
assayed in MEM (Biochrom) supplied with fetal bovine serum (10 % FBS, Merck), L-alanyl-
L-glutamine (2 mM, Biochrom), non-essential amino acids (Biochrom), sodium pyruvate (1 
mM Biochrom), NaHCO3 (0.15 % Biochrom) and gentamycin (10 µg/mL Biochrom). The 
cells were seeded in 96-well microtiter plates (Thermo Fisher Scientific) at 4000 cells/well 
  
and incubated for 24 h in 5 % CO2 at 37 °C to allow the cells to adhere before the cell media 
was replaced and the compounds added. The plates were left to incubate with the compounds 
for 72 h before 10 µL of MTS solution (CellTiter 96 Aqueous One Solution Reagent, 
Promega) was added to each well, and the cells were additionally incubated for 1 h at 37 °C. 
The absorbance at 485 nm was measured using a DTX multimode detector (Beckman 
Coulter). The negative control was defined as cells assayed with their respective cell media 
with supplemented with 1 % DMSO (1% was the highest DMSO concentration used in wells 
with fraction/compound), and positive control as cells assayed with 0.5 % Triton X-100 
(Sigma-Aldrich). Cell viability was calculated as follows: Cell survival (%) = (Absorbance 
treated wells – absorbance positive control)/(absorbance negative control – absorbance 





H NMR and 
13
C NMR data of all evaluated compounds can be viewed in the online 
version of this article at the publisher’s web site. 
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• Synthetic analo s of barretin are powerful antioxidants 
• Compound prepared display comparable activities as commercial antioxidants 
• Chan in  the hetereocyclic core alters the antioxidative properties 
• Simplifed analo s of marine natural products display improved bioactivity 
 
 
 
 
 
